Patience Precedes Profits
We regularly write about practicing patience with your winning stocks, and that will always be a key factor in making big money—unless you’re a savant, you’ll find that many of your trades will offset over time (small losses, break-evens, small wins, with...
Read More
Aggravation-to-Profit Ratio: High
Everybody loves a persistent uptrend in growth stocks, especially us; we know how to find the winners and ride them for the majority of their advance. That’s where the real money is! And while we don’t ever root for a big we...
Read More
Mixed Messages
The market is never easy to read, but the past week has been about as confusing as you’ll ever see. On one hand, leading stocks have been taken to the woodshed. Software and cybersecurity, which were two of the best performers this have...
Read More
Lots of Drama, But the Evidence is Unchanged
August is winding to a close, and we say good riddance—this month has packed in as many dramatic market-moving headlines as any we can remember due to developments in the U.S.-China trade battle, speeches from the Reserve...
Read More
Play Some Defense
Usually, when the market is doing well, stocks aren’t affected much by the news of the day. That’s not to say individual stocks don’t get pushed around, but for the market as a whole, worrisome headline news usually goes the way water...
Read More
Passing T-Storms—or Something More?
On this page of the last issue, we wrote “we think the near-term is a toss-up, at least when it comes to individual growth stocks— earnings season is always tricky, and let’s face it, many leaders have had great runs the...
Read More
Mostly Sunny—with Possible T-Storms Along the Way
Ever since January 9, when the 2-to-1 Blastoff Indicator gave a rare buy signal just two weeks after the market’s major bottom, our greatest conviction has been that the overall market had likely entered a new bull that...
Read More
The Odds Still Favor Higher Prices Ahead
It was a solid first half of 2019 for most major indexes and growth stocks. Despite a few knocks upside the head last week, our Model Portfolio finished June up nearly 22% on the year. In fact, the...
Read More
Still Going According to Script
Back on January 31, we wrote that the market was basically following a perfect Hollywood-type script for a major market bottom—you had a three-month bear phase that produced huge oversold readings and massive pessimism near the low, followed by turn...
Read More
Pieces are in Place
We’re about five weeks into this market correction, and it’s been a pretty nasty one when looking at the major indexes—from high to low, the S&P 500 has fallen as much as 7.6% and the Nasdaq by 10.8%, with small- mid-cap...
Read More
In this topsy-turvy market, it helps to know how the big hedge funds and institutions are spending their money. This Options Barometer gives you the answer.
Read More
Identifying the best ETFs of 2017 is a good predictor of what sectors have plenty of momentum heading into 2018. Here are five that stood out.
Read More
After two months of churn, biotech stocks are suddenly red-hot thanks to a blockbuster Gilead-Kite Pharma deal that's propping up the entire sector.
Read More
The best pharma stocks can be hard to find in a pharmaceutical industry rife with high-stakes conflicts over regulatory approvals, pricing and marketing.
Read More
All things considered, the past week has been tame. The S&P 600 Small Cap Index retreated 1.4% to get back to its 50-day moving average, while the S&P 500 Index traded sideways.
Read More
Once a high riser, the IHE biotech ETF has been stuck in the mud for two years. But that doesn't mean you should tune out the biopharma industry as a whole.
Read More
Stocks are rallying after Trump's win, but small cap stocks are outpacing them all. Here are three small cap sectors that are faring particularly well.
Read More
Donald Trump's surprise victory has some ETFs soaring, and some crashing. Here are the funds you should buy, and which you should avoid, in the weeks ahead.
Read More
We’re going to reel in a few profits during this post-election stock market surge in the event the honeymoon is short-lived. Along those lines, today I recommend you sell your remaining stake in Mitek (MITK), as well as sell half your position in Vascular...
Read More
We may look to exit a few positions on strength over the coming weeks/months, but those moves will depend on share price momentum and/or earnings results. More companies have announced their earnings release dates, and three companies report next week. We have ratings...
Read More
